Therapeutic Proteins and Oral Vaccines Market to Surpass US$ 316,684.7 Million by 2027 - Coherent Market Insights

Global Therapeutic Proteins and Oral Vaccines Market, by Drug Class (Therapeutic Proteins (Growth Factors, Fusion Proteins, Monoclonal Antibodies, Hormones, Coagulation Factors, and Others) and Oral Vaccines (Live Attenuated Vaccine, Inactivated Vaccine, Recombinant Vaccine, and Others), by Application (Oncology, Hematology, Immunology, Endocrinology, Infectious Disease, Cardiovascular Disease, and Others), by Distribution Channel Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 201,042.7 million in 2020 and is expected to exhibit a CAGR of 6.7 % over the forecast period (2020-2027), as highlighted in a new report published by Coherent Market Insights.

Global therapeutic proteins and oral vaccines market is expected to witness significant growth due to key companies focusing on product approvals. For instance, In October 2108, Sandoz, a Novartis’ division, received the U.S. Food and Drug Administration (FDA) approval for its Hyrimoz (adalimumab-adaz), a biosimilar to AbbVie Inc.’s Humira. However, the company settled with AbbVie Inc. to delay its launch and is expected to launch it in 2023

Moreover, In 2018, Sanofi received the U.S. Food and Drug Administration approval for its Dupixent (dupilumab) as an add-on maintenance therapy for patients with moderate-to-severe asthma aged 12 years and older with an eosinophilic phenotype or with oral corticosteroid-dependent asthma

Moreover, key companies focusing on inorganic strategies such as collaborations to strengthen their position in the market. For instance, in September 2020, Eli Lilly and Company and Amgen announced a global antibody manufacturing collaboration to significantly increase the supply capacity available for Lilly's potential COVID-19 therapies. Through this collaboration, the two companies will have the ability to quickly scale up production and serve more patients with one or more of Lilly's antibody therapies.

Global Therapeutic Proteins and Oral Vaccines Market – Impact of Coronavirus (Covid-19)

• The COVID-19 pandemic has drastically affected each and every market around the globe and it is expected to affect the global therapeutic proteins and oral vaccines market as follows:
• There has been a negative impact on ongoing clinical trials of therapeutic proteins and oral vaccines for treatment of cancer such as lung cancer and others, as academic institutes, research institutes and pharmaceutical companies have shifted their focus to research and development of COVID-19 treatments.
• According to Pediatric Policy Council, (combined legislative advocacy of the Academic Paediatric Association) report published in June 2020, status of ongoing clinical trials has been modified to enable home administration of treatment and virtual monitoring to minimize risk of COVID-19 infection, and to avoid diversion of healthcare resources from responding to COVID-19 cases. Moreover, most clinical trials are been paused, except those testing life-saving therapies. Thus, COVID-19 has negatively impacted the research and development activities of various drug molecules for treatment of chronic diseases such as cancer, haematological disorders.

Browse 40 Market Data Tables and 33 Figures spread through 327 Pages and in-depth TOC on “Global Therapeutic Proteins and Oral Vaccines Market, by Drug Class (Therapeutic Proteins (Growth Factors, Fusion Proteins, Monoclonal Antibodies, Hormones, Coagulation Factors, and Others) and Oral Vaccines (Live Attenuated Vaccine, Inactivated Vaccine, Recombinant Vaccine, and Others), by Application (Oncology, Hematology, Immunology , Endocrinology, Infectious Disease, Cardiovascular Disease, and Others), by Distributing Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)’

To know the latest trends and insights prevalent in the Global Therapeutic Protein and Oral Vaccines Market, click the link below:

https://www.coherentmarketinsights.com/market-insight/therapeutic-proteins-and-oral-vaccines-market-4396

The market is expected to gain significant growth during the forecast period, as various key companies are focusing on product launches in the market. For instance, in October 2017, Serum Institute of India launched two new products in the market Rotasiil and Rabishield for rotavirus causing diarrhea and rabies, respectively. Rotasiil, rotavirus oral vaccine is the world's first thermostable pentavalent Rotavirus vaccine containing the G9 strain to help prevent the spread of rotavirus, which causes diarrhea mostly in babies.

Key Takeaways of the Global Therapeutic Proteins and Oral Vaccines Market:

• The global therapeutic proteins and oral vaccines market is expected to exhibit a CAGR of 6.7% over the forecast period, owing to increasing prevalence of chronic diseases and rising number of clinical trials by major companies. According to National Center for Biotechnology Information (NCBI), 2018, incidence of inflammatory bowel movement (IBD) in North America ranges from 2.2- 19.2 cases per 100,000 person for ulcerative colitis. Moreover, prevalence in the U.S. for adult ulcerative colitis was 238 per 100,000 population
• Among drug class, therapeutic proteins segment is expected to hold a dominant position in the therapeutic protein and oral vaccine market in 2020, due to increase product launches by the key players. For instance, in 2018, Sanofi and Regeneron Pharmaceuticals, Inc. announced that the U.S. FDA accepted a supplemental Biologics License Application (sBLA) for Praluent (alirocumab) Injection, a PCSK9 inhibitor
• Among application, oncology segment is expected to hold dominant position in the therapeutic protein and oral vaccine market in 2020, owing to increase in prevalence of cancer such as lung cancer, leukemia in adultsor instance, in 2017, Mundipharma GmbH launched its Truxima (rituximab), a biosimilar monoclonal antibody for the treatment of cancer, in the UK, Germany, Italy, the Netherlands, Belgium, Republic of Ireland, and Luxembourg, following authorization by the European Medicines Agency (EMA).
• Among distribution channel, hospital pharmacies segment is expected to hold a dominant position in the therapeutic protein and oral vaccine market in 2020, owing to rising prevalence of various diseases such as non-small cell lung cancers, leukemia, osteoporosis, diabetes mellitus and multiple sclerosis. According to the Multiple Sclerosis Foundation, 2017, MS autoimmune condition affects 2.5 million people with the global incidence of around 7 cases per 100,000 people per year
• Key players operating in the global therapeutic proteins and oral vaccines market include Abbott Laboratories, Amgen, Inc., Biogen, Inc, Eily, Lilly, and Company, F. Hoffmann-La Roche, Johnson and Johnson, Merck & Co., Novo Nordisk, Pfizer, Inc., Sanofi S.A., Serum Institute of India Pvt. Ltd., Emergent Biosolutions Inc. , TransAlgae, MigVax Ltd, and Lumen Bioscience, Inc